16,676 Shares in CG Oncology, Inc. $CGON Bought by Fox Run Management L.L.C.

Key Points

• Fox Run Management L.L.C. made a new investment in CG Oncology, Inc. with a purchase of 16,676 shares totaling approximately $408,000 during the first quarter.
• Several large investors, including Wells Fargo and Invesco, have significantly increased their stakes in CG Oncology over the past quarter, indicating growing institutional interest.
• Analyst ratings for CG Oncology vary widely, with a consensus rating of "Moderate Buy" and an average price target of $55.30, while the stock is currently trading at around $26.13.

Fox Run Management L.L.C. purchased a new stake in shares of CG Oncology, Inc. (NASDAQ:CGON - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 16,676 shares of the company's stock, valued at approximately $408,000.

A number of other institutional investors have also recently made changes to their positions in the company. Wells Fargo & Company MN lifted its holdings in CG Oncology by 45.3% during the 4th quarter. Wells Fargo & Company MN now owns 28,234 shares of the company's stock worth $810,000 after purchasing an additional 8,803 shares in the last quarter. Deutsche Bank AG lifted its holdings in CG Oncology by 53.5% during the 4th quarter. Deutsche Bank AG now owns 38,978 shares of the company's stock worth $1,118,000 after purchasing an additional 13,589 shares in the last quarter. Rhumbline Advisers lifted its holdings in CG Oncology by 8.2% during the 1st quarter. Rhumbline Advisers now owns 74,689 shares of the company's stock worth $1,829,000 after purchasing an additional 5,673 shares in the last quarter. GAMMA Investing LLC lifted its holdings in CG Oncology by 1,051.0% during the 1st quarter. GAMMA Investing LLC now owns 2,302 shares of the company's stock worth $56,000 after purchasing an additional 2,102 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in CG Oncology by 3.5% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,080 shares of the company's stock worth $862,000 after purchasing an additional 1,026 shares in the last quarter. Hedge funds and other institutional investors own 26.56% of the company's stock.

Insider Buying and Selling at CG Oncology

In other news, Director Leonard E. Post sold 2,000 shares of the business's stock in a transaction on Thursday, July 17th. The stock was sold at an average price of $28.00, for a total value of $56,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

CG Oncology Stock Performance

Shares of NASDAQ CGON traded up $0.94 during mid-day trading on Friday, hitting $26.92. 542,477 shares of the stock traded hands, compared to its average volume of 694,966. The stock has a fifty day moving average price of $26.11 and a 200-day moving average price of $25.30. The company has a market cap of $2.05 billion, a price-to-earnings ratio of -15.21 and a beta of 0.87. CG Oncology, Inc. has a 52 week low of $14.80 and a 52 week high of $40.47.

CG Oncology (NASDAQ:CGON - Get Free Report) last announced its quarterly earnings data on Friday, August 8th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.05). CG Oncology had a negative net margin of 15,945.17% and a negative return on equity of 19.37%. As a group, sell-side analysts predict that CG Oncology, Inc. will post -1.31 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

CGON has been the topic of a number of recent research reports. Piper Sandler initiated coverage on CG Oncology in a report on Monday, August 18th. They set an "overweight" rating and a $55.00 price objective on the stock. The Goldman Sachs Group upgraded CG Oncology to a "strong-buy" rating and set a $40.00 target price on the stock in a research note on Thursday, July 10th. Wall Street Zen lowered CG Oncology from a "hold" rating to a "sell" rating in a research note on Saturday, August 9th. Cantor Fitzgerald restated an "overweight" rating and issued a $75.00 target price on shares of CG Oncology in a research note on Monday, April 28th. Finally, JPMorgan Chase & Co. began coverage on CG Oncology in a research note on Friday, May 2nd. They issued an "overweight" rating and a $41.00 target price on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $55.27.

CG Oncology Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.